Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| GPRC5D VHH - 01 | PCC | Hematological Malignancy | Multiple myeloma |
FACS Analysis of CHO/Human GPRC5D Stable Cell Line.
FACS assay shows that Anti-GPRC5D antibody can bind to CHO/Human GPRC5D Stable Cell Line (Fig. B), and non-transfected CHO cells were used as a negative control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).
Anti-GPRC5D Antibody, Human IgG4 captured on Protein A Chip can bind Human GPRC5D Full Length Protein, Flag,His Tag (Cat. No. GPD-H52D5) with an affinity constant of 57.7 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Talquetamab | JNJ-7564; JNJ-64407564 | Approved | Johnson & Johnson Innovative Medicine, Genmab A/S | TALVEY | United States | Multiple Myeloma | Janssen Biotech Inc | 2023-08-09 | Hematologic Neoplasms; Multiple Myeloma | Details |
| Talquetamab | JNJ-7564; JNJ-64407564 | Approved | Johnson & Johnson Innovative Medicine, Genmab A/S | TALVEY | United States | Multiple Myeloma | Janssen Biotech Inc | 2023-08-09 | Hematologic Neoplasms; Multiple Myeloma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| LM-305 | LM-305 | Phase 2 Clinical | LaNova Medicines Ltd | Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
| BCMA-GPRC5D CAR-T Cells Therapy(Wuhan Union Hospital) | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital | Multiple Myeloma | Details | |
| MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
| CT-071 | CT071; CT-071 | Phase 2 Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy（920th Hospital） | Phase 2 Clinical | The 920th Hospital Of Joint Logistics Support Force Of PLA | Multiple Myeloma | Details | |
| Ori-CAR-017 | Ori-CAR-017; OriCAR-017; GPRC5D-CAR-T | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Hematologic Diseases; Hemorrhagic Disorders; Immunoproliferative Disorders; Hemostatic Disorders; Paraproteinemias; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Immune System Diseases; Vascular Diseases; Neoplasms, Plasma Cell; Cardiovascular Diseases; Lymphoproliferative Disorders | Details |
| LBL-034 | LBL-034 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Neoplasms; Multiple Myeloma | Details |
| CC-95266 | CC-95266; BMS986393; BMS-986393 | Phase 2 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) | BMS-986453 | Phase 1 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| SIM-0500 | SIM-0500; SIM0500 | Phase 1 Clinical | Hainan Xiansheng Re Ming Pharmaceutical Co Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | Zhejiang University, OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
| CAR-GPRC5D | CAR-GPRC5D | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Forimtamig | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| MCARH-109 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc | Multiple Myeloma | Details | |
| RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) | The Second People Hospital Of Guangdong Province | Details | |||
| Anti-GPRC5D CAR-T Cells Therapy（Institute of Hematology & Blood Diseases Hospital） | Institute Of Hematology & Blood Diseases Hospital | Details | |||
| LM-305 | LM-305 | Phase 2 Clinical | LaNova Medicines Ltd | Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
| BCMA-GPRC5D CAR-T Cells Therapy(Wuhan Union Hospital) | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital | Multiple Myeloma | Details | |
| MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
| CT-071 | CT071; CT-071 | Phase 2 Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy（920th Hospital） | Phase 2 Clinical | The 920th Hospital Of Joint Logistics Support Force Of PLA | Multiple Myeloma | Details | |
| Ori-CAR-017 | Ori-CAR-017; OriCAR-017; GPRC5D-CAR-T | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Hematologic Diseases; Hemorrhagic Disorders; Immunoproliferative Disorders; Hemostatic Disorders; Paraproteinemias; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Immune System Diseases; Vascular Diseases; Neoplasms, Plasma Cell; Cardiovascular Diseases; Lymphoproliferative Disorders | Details |
| LBL-034 | LBL-034 | Phase 2 Clinical | Nanjing Leads Biolabs Co Ltd | Neoplasms; Multiple Myeloma | Details |
| CC-95266 | CC-95266; BMS986393; BMS-986393 | Phase 2 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) | BMS-986453 | Phase 1 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| SIM-0500 | SIM-0500; SIM0500 | Phase 1 Clinical | Hainan Xiansheng Re Ming Pharmaceutical Co Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | Zhejiang University, OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
| CAR-GPRC5D | CAR-GPRC5D | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Forimtamig | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| MCARH-109 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc | Multiple Myeloma | Details | |
| RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) | The Second People Hospital Of Guangdong Province | Details | |||
| Anti-GPRC5D CAR-T Cells Therapy（Institute of Hematology & Blood Diseases Hospital） | Institute Of Hematology & Blood Diseases Hospital | Details |
This web search service is supported by Google Inc.
A-Z
